Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma
E. M. Ringwalt, M. A. Currier, A. M. Glaspell, C.-Y. Chen, M. V. Cannon, M. Cam, A. C. Gross, M. Gust, P.-Y. Wang, L. Boon, L. E. Biederman, E. Schwarz, P. Rajappa, D. A. Lee, E. R. Mardis, , T. P. Cripe
This study shows trabectedin enhances oncolytic virotherapy by reducing anti-viral barriers and boosting immune-mediated tumor regression in preclinical models.
bioRxiv · Mar 2, 2024Cancer Biology